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Abstract 
E-cigarette vapour contains free radicals with the potential to induce oxidative stress. Since 
oxidative stress in airway cells increases platelet-activating factor receptor (PAFR) 
expression, and PAFR is co-opted by pneumococci to adhere to host cells, we hypothesised 
that E-cigarette vapour increases pneumococcal adhesion to airway cells.  
 
Nasal epithelial PAFR was assessed in non-vaping controls, and in adults before and after 5 
min of vaping. We determined the effect of vapour on oxidative stress-induced, PAFR-
dependent pneumococcal adhesion to airway epithelial cells in vitro, and on pneumococcal 
colonisation in the mouse nasopharynx. Elemental analysis of vapour was done by mass 
spectrometry, and oxidative potential of vapour assessed by antioxidant depletion in vitro.  
 
There was no difference in baseline nasal epithelial PAFR expression between vapers (n=11) 
and controls (n=6). Vaping increased nasal PAFR expression. Nicotine-containing and 
nicotine-free E-cigarette vapour increased pneumococcal adhesion to airway cells in vitro. 
Vapour-stimulated adhesion in vitro was attenuated by the PAFR blocker CV3988. Nicotine-
containing E-cigarette vapour increased mouse nasal PAFR expression, and nasopharyngeal 
pneumococcal colonisation. Vapour contained redox-active metals, had considerable 
oxidative activity, and adhesion was attenuated by the antioxidant N-acetyl cysteine.  
 
This study suggests that E-cigarette vapour has the potential to increase susceptibility to 
pneumococcal infection.  
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Introduction 
Epidemiological studies suggest that inhalation of toxins increases the risk of airway bacterial 
infection. For example, cigarette smoking is associated with a 4 fold (95% CI; 2 - 7) 
increased risk of invasive pneumococcal disease (1), passive exposure to environmental 
tobacco smoke is associated with a 1.5 fold (95% CI; 1.2 - 1.9) risk of pneumonia in children 
(2), and in young children, exposure to fossil fuel-derived particulate matter is associated 
with a 1.3 fold (95% CI; 1.0 - 1.6) increase in bacterial pneumonia (3). Increased risk of 
pneumococcal infection, the commonest cause of bacterial pneumonia (4), is also reported in 
occupational and environmental settings, including exposure to welding fumes (5), and 
airborne dust (6). Since invasive pneumococcal strains adhere to, and translocate across, 
respiratory tract epithelial cells, adhesion is a prerequisite for establishing pneumococcal 
disease (4). To establish firm adhesion, pneumococci co-opt host-expressed platelet 
activating factor receptor (PAFR), and then use the receptor as a Trojan horse to enter airway 
cells as the receptor is internalised (7). Previous studies suggest that upregulation of PAFR is 
a biologically plausible mechanism for the association between inhalation of toxins and 
vulnerability to pneumococcal infection. For example, we found that cigarette smoke extract, 
fossil fuel-derived particulate matter, and welding fumes, via the induction of oxidative 
stress, upregulate PAFR-dependent pneumococcal adhesion to lower airway cells in vitro (8-
10).   
 
Electronic cigarettes (EC) are marketed to adults and young people as a safer alternative to 
smoking and a potential smoking cessation aid. The vapour from Electronic cigarettes, 
generated by the vaporisation of propylene glycol (1,2-propandiol), glycerin, nicotine, and 
flavourings in EC liquid, contains fewer toxic compounds compared with tobacco smoke 
(11). Although it is speculated that some adverse health effects of inhaling EC vapour are 
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reduced compared with tobacco smoke, there is emerging evidence of toxic effects incuding 
the capacity to impair pulmonary bacterial host defences. For example in mice, EC vapour 
depletes lung antioxidants and delays the clearance of pneumococci from the lung (12, 13). 
We therefore hypothesised that EC vapour increases PAFR-dependent pneumococcal 
adhesion to airway cells. To address this hypothesis, we sought in the present study to 
determine; i) the effect of vaping on nasal epithelial PAFR expression in adults, ii) the effect 
of EC vapour on PAFR-dependent pneumococcal adhesion to airway cells in vitro, and iii) 
the effect of EC vapour on nasal PAFR expression and nasal pneumococcal burden in a 
mouse model of asymptomatic nasopharyngeal pneumococcal colonisation. 
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Methods 
 
Human volunteer study 
Adults who vaped at least once a week, and healthy never-smoked adult controls were 
recruited. Exclusion criteria were; tobacco cigarette smoking within 3 mo (for vapers), any 
tobacco smoking (for controls), chronic respiratory disease, recent nasal surgery, and nasal 
therapy. Nasal epithelial cell samples were obtained from both nostrils of participants using a 
Rhino-probeTM (VWR, Radnor, USA) and pooled in primary cell media (Promocell, 
Heidelberg, Germany) containing penicillin-streptomycin and primocin (InvivoGen, France). 
In vapers, nasal cells were obtained immediately before, and 1 h post, EC use. Vaping was 
over an observed 5 min period. Vapers were asked to inhale EC vapour at their normal 
frequency and to exhale normally. Nasal biopsies were taken from controls on a single 
occasion. To assess PAFR expression, nasal cells were washed and resuspended in DPBS 
containing 10% FBS before staining with an anti-PAFR primary antibody (1:200, Abcam, 
Cambridge, UK) as described above. E-cadherin (primary antibody used at 1:100, Abcam) 
was added to identify epithelial cells (14). Cells were washed, and then stained with 
secondary antibodies conjugated to Alexa Fluor 488 for PAFR expression (1:3000, Abcam) 
and conjugated to APC for E-cadherin expression (1:1500, Abcam) for 30 min with shaking 
at room temperature. A PAFR isotypic control (rabbit IgG monoclonal EPR25A) was 
included to adjust for nonspecific immunostaining. Analysis was carried out on the BD 
FACS Canto II machine using BD FACSDiva software (BD Biosciences, Oxford, UK) with 
gating set to exclude cell debris. PAFR expression correcting for non-specific staining, was 
expressed as median fluorescence intensity (MFI). The study was approved by a UK National 
Health Service Research Ethics Committee (15/NE/0237), and required written consent. 
 
E-cigarette vapour  
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Electronic-cigarette vapour was collected onto cotton filters through a peristaltic pump 
(Jencons Scientific Ltd. East Grinstead, UK) at a fixed rate, from a second-generation EC 
(RBC CE5 Clearomizer, 3.7V 650mAh power supply battery, purchased online from 
https://www.ukecigstore.com, UK). Filters were exposed to 25 puffs over 5 min using either 
tobacco-flavoured EC liquid containing 24 mg/mL nicotine, or nicotine-free tobacco-
flavoured EC liquid (purchased online from https://www.ukecigstore.com). EC vapour 
extract (ECV) was obtained from filters by vortexing in 2 mL Dulbecco’s phosphate buffered 
saline (DPBS), and stored as 100% stock solution at -20°C. Medium control stocks were 
made by extracting 2 mL DPBS from the cotton filters (DPBS control extract). Pure nicotine 
(Sigma-Aldrich, Poole, UK) was diluted in DPBS to produce a stock solution. The 
concentration of nicotine in ECV and EC liquid was measured by gas chromatography–mass 
spectrometry (GC-MS; online supplement). 
 
Airway cells 
The alveolar type II epithelial cell line A549 was purchased from Sigma-Aldrich (Poole, UK) 
and maintained in DMEM supplemented with foetal bovine serum (FBS) and penicillin-
streptomycin (Lonza, Basel, Switzerland), and passage number less than 20. The bronchial 
epithelial cell line BEAS-2B was maintained in RPMI-1640 (Life Technologies) and 
supplemented with FBS and penicillin-streptomycin and passage number was less than 20. 
Human primary bronchial epithelial cells (HBEpC) were purchased from Promocell GmbH 
(Heidelberg, Germany) and maintained as per manufacturer’s instructions and passage 
number was less than 5. Human primary nasal epithelial cells (HPNEpC) were obtained from 
a never-smoked, non-vaping female adult donor using a Rhino-probeTM, and maintained in  
BEGM™ Bronchial Epithelial Cell Growth Medium supplemented with the BEGM BulletKit 
as per manufacturer’s instructions (Lonza) and with passage number less than 5. The 
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presence of epithelial cells were confirmed by assessing the total percentage of cells stained 
with epithelial marker E-cadherin, assessed by flow cytometry (described above). Cell 
membrane integrity was assessed by lactate dehydrogenase release, according to the 
manufacturer’s instructions (Sigma-Aldrich). Treatment of cells with distilled water was used 
as a positive control, and indicated 100% LDH release.  
 
Adhesion and PAFR  
The virulent type 2 Streptococcus pneumoniae encapsulated strain D39 (NCTC 7466) was 
purchased from the National Collection of Type Cultures (Central Public Health Laboratory, 
London, UK) grown to mid-logarithmic phase (OD600 = 0.4 to 0.6) in brain heart infusion 
broth (BHI) (Oxoid, Hampshire, UK) and stored at -80 °C.  Pneumococcal adhesion to 
airway cells was conducted using an in vitro adhesion assay (8, 9). In this assay colony 
forming unit counts per mL (CFU) reflects both the number of pneumococci adherent to the 
surface of cells and the number of intracellular bacteria (online supplement). The intracellular 
component was assessed after first killing surface adherent bacteria with penicillin (200 
mg/mL) and gentamicin (10 mg/mL) for 30 min. Intracellular pneumococci that were 
protected from antibiotic killing were recovered by cell lysis with ice-cold sterile water and 
plated on BHI agar to determine CFU (8). The role of oxidative stress was determined by 
incubating cells with the thiol antioxidant N-acetylcysteine (NAC; Sigma-Aldrich), at a final 
concentration 5 mmol/L (15). Cells were incubated with NAC both 30 min before exposure 
to ECV, and during ECV exposure. NAC was removed by washing prior to adding 
pneumococci and assessing adhesion. The role of PAFR was assessed by adding CV3988 
(Sigma Aldrich), a specific PAFR receptor blocker with a half maximal inhibitory 
concentration (IC50) of 0.28 µM (16). CV3988 was added to the adhesion assay at a final 
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concentration of 20 µM, as previously reported (17). We sought to establish complete results 
in A549 cells then confirm key findings in other airway cells.  
 
To assess PAFR expression, airway cells were detached from cell culture flasks with trypsin 
and washed before resuspension in DPBS containing 10% FBS and stained with an anti-
PAFR primary antibody (1:200, Abcam, Cambridge, UK) for 1 h with shaking at room 
temperature. A PAFR isotype control (rabbit IgG monoclonal EPR25A) was included to 
control for nonspecific staining. Analysis was carried out on the BD FACS Canto II machine 
using BD FACSDiva software (BD Biosciences, Oxford, UK). PAFR is expressed as median 
fluorescence intensity (MFI).  
 
Mouse pneumococcal colonisation model 
Female CD1 mice 6 to 8 weeks of age (Charles River, Margate, UK) were dosed twice daily 
with 100% stock solution nicotine-containing ECV, nicotine-free ECV, or a DPBS control 
extract for the duration of the experiment. On day 4 of dosing, 1 x105 CFU S. pneumoniae in 
10 µL PBS was instilled into the nasal cavity under anaesthesia, to induce asymptomatic 
nasopharyngeal carriage. Four days post inoculation, nasopharyngeal tissues were 
homogenised and washed through a cell strainer. Pneumococcal CFU were determined by 
Miles and Misra viable counts as previously described (18). Nasal PAFR expression was 
determined by flow cytometry (online supplement). Animal experiments were performed at 
the University of Liverpool in accordance with the Animal Scientific Procedures Act 1986 
and with the prior approval of the UK Home Office (PPL 40/3602) and the University of 
Liverpool animal welfare and ethics committee. 
 
Elemental analysis and oxidative potential 
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Elemental composition was determined by induction coupled plasma-mass spectrometry 
(ICP-MS) using a PerkinElmer ICP mass spectrometer NexION 350D, following acid 
digestion (online supplement). The oxidative potential (OP) of ECV was determined by 
quantifying the loss of two low molecular weight antioxidants ascorbate and glutathione in 
synthetic human respiratory tract lining fluid (RTLF) over a 4 h incubation period at 37°C, 
pH 7.0, using our previously reported method (19) (online supplement). Data are expressed 
as the percentage loss of ascorbate and glutathione relative to the 4 h DPBS control. Included 
in assays were i) a negative control PM with low OP (M120; a 50 nm carbon black particle 
with simple surface chemistry (20)), and ii) a particle with higher OP - the urban PM standard 
SRM-1648 (National Institute of Standards and Technology, Gaithersburg, Md., USA). 
Particles were used at a final concentration of 50 µg/mL 
 
Statistical analysis 
Data from studies of human volunteers, animals, and OP are summarised as mean (standard 
error of the mean; SEM) and analysed by either t test, or by one way analysis of variance 
(ANOVA) with post hoc multiple comparison testing. Data from in vitro adhesion studies are 
from at least 4 experiments, unless stated, conducted at different times, representing the mean 
of at least 3 replicates, and are summarised as median (IQR; interquartile range) and analysed 
by Kruskal-Wallis with post hoc multiple comparison testing. Analyses were done using 
Prism 7 (GraphPad Software Inc., La Jolla, CA, USA) and a p value of <0.05 was considered 
statistically significant. 
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Results 
 
Vaping and nasal PAFR expression  
Eleven vaping adult males (mean age; 30 + 3 yr., table), and 6 male controls (mean age; 39 + 
5 yr.) were studied. Ten vaping subjects used nicotine-containing EC liquid, and one (subject 
3, table) used nicotine-free EC liquid. All vapers inhaled more than 10 puffs over 5 min, 
exhaled vapour via both mouth and nose, and had not vaped over the previous 12 h. Nasal 
PAFR expression prior to ECV inhalation was not significantly different from non-vaping 
controls (figure 1a). Vaping increased nasal PAFR at 1 h (p <0.05 vs. baseline, figure 1b), 
and nasal PAFR 1 h post-vaping was increased compared with controls (5778+1692 vs. 
837+447 MFI,  p <0.05).  
 
Human alveolar epithelial A549 cells 
Both nicotine-free and nicotine-containing ECV increased pneumococcal adhesion to A549 
cells in a dose-dependent manner (figure 2a), and a time-dependent manner (figure 1, online 
supplement). Exposure of cells to 5% ECV for 2.5 h did not cause A549 cell membrane 
damage, as assessed by LDH release (figure 2, online supplement), and this dose and duration 
was therefore used in subsequent experiments. Pneumococcal penetration into cells, assessed 
after killing cell surface bacteria, was increased by both nicotine-free and 5% nicotine-
containing ECV (p <0.05 and p <0.01 respectively, figure 2b). Both 5% nicotine-free and 
nicotine-containing ECV increased PAFR expression (p <0.01 and p <0.001 respectively, 
figure 2c), and the PAFR antagonist CV3988 attenuated pneumococcal adhesion stimulated 
by both 5% nicotine-free and nicotine-containing ECV (p <0.05 and p <0.01 respectively, 
figure 2d). CV3988 did not attenuate low level “basal” pneumococcal adhesion to unexposed 
cells (figure 2d). The antioxidant NAC completely attenuated pneumococcal adhesion 
stimulated by both 5% nicotine-free and nicotine-containing ECV (p <0.05, figure 3a). NAC 
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did not attenuate “basal” pneumococcal adhesion to unexposed cells (figure 3a). Incubation 
of A549 cells with dilutions of nicotine in DPBS increased adhesion at 2.5 mg/mL (p <0.01 
vs. control, figure 3, online supplement), with no increase in adhesion at lower 
concentrations. There was no difference in pneumococcal adhesion stimulated by either 
freshly generated- or frozen ECV (data not shown). 
 
Other human airway epithelial cells 
The antioxidant NAC completely attenuated pneumococcal adhesion to BEAS-2B cells 
stimulated by both 5% nicotine-free ECV and nicotine-containing ECV (p <0.05, Figure 3b). 
5% nicotine-free ECV increased pneumococcal adhesion in HPNEpC primary nasal cells (p 
<0.05), primary bronchial (HBEpC) cells (p <0.05) and BEAS-2B bronchial epithelial cells 
(p <0.05, figure 4a-c). 5% nicotine-containing ECV increased pneumococcal adhesion to 
HPNEpC primary nasal cells (p <0.05), HBEpC primary bronchial cells (p <0.01), and 
BEAS-2B cells (p <0.01, figure 4a–c). The PAFR blocker CV3988 attenuated pneumococcal 
adhesion stimulated by 5% nicotine-free ECV in HPNEpC primary nasal (p <0.05), HBEpC 
primary bronchial (p <0.05) and BEAS-2B cells (p <0.05, figure 4a-c). CV3988 also 
attenuated 5% nicotine-containing ECV stimulated pneumococcal adhesion in HPNEpC 
primary nasal cells (p <0.05), primary bronchial HBEpC cells (p <0.05), and BEAS-2B cells 
(p <0.01, figure 4a–c).  
 
5% nicotine-free ECV increased PAFR expression in HPNEpC primary nasal cells (p <0.05), 
HBEpC primary bronchial (p <0.05), and BEAS-2B cells (p <0.01, figure 5a - 5c). 5% 
nicotine-containing ECV increased PAFR expression in HPNEpC primary nasal cells (p 
<0.001), primary bronchial HBEpC (p <0.01) and BEAS-2B cells (p <0.001, figure 5a–c).   
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In 8/11 vapers sufficient cells from the baseline biopsy were obtained for culture with 5% 
nicotine-containing  ECV in vitro. In these primary nasal cells from vapers, PAFR expression 
in vitro was increased by 5% nicotine-containing ECV for 2.5 h (p <0.01 vs. medium control, 
figure 5d).  
 
Pneumococcal colonisation of the nasopharynx 
Intranasal instillation of 100% nicotine-free ECV did not increase either PAFR expression 
(figure 6) or nasopharyngeal CFU (figure 6). By contrast, prior exposure to 100 % nicotine-
containing ECV increased nasopharyngeal pneumococcal CFU at 4 days post intranasal 
instillation of bacteria (p <0.05 vs. control, figure 6a), and increased nasal epithelial PAFR 
expression 4 days post exposure (p  <0.001 vs. control, figure 6).  
 
Elemental composition and oxidative potential 
Both 5% nicotine-free and nicotine-containing ECV contained metals with the capacity to 
induce oxidative stress (table, online supplement). Although the elemental composition of the 
two extracts was broadly similar, the concentration of copper in nicotine-containing ECV was 
increased (p <0.05 vs. nicotine-free, Table, online supplement). Both 5% nicotine-free and 
nicotine-containing ECV extract oxidised ascorbate (p <0.0001 vs. low OP particle control, 
figure 7a). The percentage loss for ascorbate of 5% nicotine-containing ECV was increased 
compared with the particle with higher OP particle (p <0.0001), and was increased compared 
with the nicotine-free ECV (p <0.0001, figure 7a). A similar pattern was found for 
glutathione depletion, with higher percentage loss observed with nicotine-containing ECV 
relative to the low and higher OP particle (p <0.0001, figure 7b), and increased OP compared 
with the nicotine-free ECV (p <0.001, figure 7b). 
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Nicotine  
The nicotine concentration of nicotine-containing E-liquid was 24 mg/mL -  identical to that 
reported by the manufacturer. Nicotine-free E-liquid contained only a trace of nicotine, and 
the DPBS control extract contained no nicotine. The nicotine concentration of 5% nicotine-
free ECV was just above assay’s level of detection at 0.03 mg/mL, and 5% nicotine-
containing ECV contained 0.4 mg/mL. 
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Discussion 
 
In this study, we sought to assess whether exposure of the airway epithelium to Electronic 
cigarette vapour increases its capacity to support pneumococcal adhesion and infection. In 
adult volunteers we found that vaping increases nasal epithelial PAFR expression, and that 
post-vaping PAFR expression is higher than non-exposed controls. PAFR expression is not 
persistently increased by vaping, since pre-vaping levels are not higher than controls. 
Compatible with reports of increased pneumococcal adhesion to airway cells exposed to 
toxins such as cigarette smoke (8), welding fumes (10), and fossil-fuel-derived particulate 
matter (9), we found that ECV increases pneumococcal adhesion to airway epithelial cells in 
vitro.  
 
Adhesion stimulated by ECV in vitro is due to increased PAFR expression, since ECV 
markedly increases expression of PAFR on airway cells, and the PAFR blocker CV3988 
completely attenuates ECV-stimulated adhesion in nasal, bronchial, and alveolar epithelial 
cells. This effect of CV3988 is compatible with previous reports that blocking PAFR 
attenuates increased pneumococcal adhesion stimulated by either inflammatory mediators 
(21), or by toxins that induce oxidative stress (10, 22). The lack of effect of CV3988 on 
control cells is also compatible with reports that low level “basal” adhesion to unstimulated 
cells is mediated by a PAFR-independent, as yet undefined, mechanism (21).  
 
There is evidence from previous studies that ECV has the potential to induce oxidative stress 
in airway cells. For example, Goel et al (23) reported that ECV contains up to 10 x 1013 free 
radicals per puff (23), Carnival et al (24) reported increased circulating oxidative stress 
markers in adults after vaping, and Solleti et al (25) reported that ECV is a potent inducer of 
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oxidative stress response genes in bronchial epithelial cells in vitro. In the present study, the 
high OP of ECV, the presence in ECV of redox-promoting metals such as copper and iron, 
and attenuation of ECV-stimulated pneumococcal adhesion by the antioxidant N-acetyl 
cysteine, supports a role for oxidative stress as the initial stimulus for PAFR-dependent 
adhesion. By contrast, the role of nicotine per se in upregulating pneumococcal adhesion is 
more complex. On one hand, nicotine increases both PAFR expression and pneumococcal 
adhesion in A549 cells - results compatible with Shen et al (26) who reported that nicotine 
increases PAFR mRNA expression in A549 cells. On the other hand, PAFR-dependent 
adhesion is also increased by nicotine-free ECV. Furthermore, the concentration of nicotine 
in 5% nicotine-containing ECV (0.4 mg/mL) is below the concentration (2.5 mg/mL) 
required to significantly stimulate adhesion in vitro when used as diluted pure compound. We 
therefore conclude that, for in vitro responses, other compounds in ECV such as redox active 
metals stimulate PAFR-dependent adhesion. By contrast, the role of nicotine in stimulating 
increased nasal PAFR in vivo remains unclear. Of note, however, is that PAFR expression 
increased with vaping in the adult who used nicotine-free EC liquid. Future studies in vaping 
adults should therefore aim to compare nasal PAFR responses to nicotine-containing ECV, 
nicotine-free ECV, and pure nicotine nasal spray. 
 
There are several limitations to this study. First, it is unclear whether the concentration and 
duration of ECV used in vitro reflects exposure of airway cells in vivo. However, the increase 
in nasal PAFR expression with vaping, and increase in PAFR in nasal cells obtained at 
baseline from vapers and exposed to ECV extract in vitro, suggests that our in vitro model is 
valid. Second, we did not, for ethical reasons, determine whether ECV-induced nasal PAFR 
expression increases pneumococcal infection in humans- but this is well established in animal 
models. For example in a model of invasive pneumococcal disease, Cundell et al (21) 
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reported that exposure of rabbits to interleukin-1α , a mediator that upregulates epithelial 
PAFR, increases pneumococcal CFU in lung lavage. In our mouse model of asymptomatic 
pneumococcal nasal colonisation, exposure to nicotine-containing ECV increases both nasal 
PAFR expression and nasopharyngeal pneumococcal CFU load. By contrast, nicotine-free 
ECV does not either increase nasal PAFR or pneumococcal CFU. Overall, these data suggest 
that nasal PAFR expression prior to pneumococcal exposure directly influences subsequent 
nasal colonisation. Indeed, in the study of Cundell et al (21), attenuation of pneumococcal 
airway infection by a PAFR antagonist, was associated with a reduction in nasal colonisation 
by over 90%. Since pneumococcal disease in humans is preceded by asymptomatic 
colonisation (27), we speculate that expression of PAFR in the upper airway is clinically 
relevant. The reason why nicotine-free ECV has no effect in the mouse model is unclear, but 
this may be due to its lower OP compared with nicotine-containing ECV. A third limitation is 
that, reflecting our local vaping population, only males were recruited. Thus sex differences 
in nasal responses cannot be excluded. Finally, we did not study the effect of ECV on the 
adhesion of other bacteria that co-opt PAFR to adhere to human cells including non-typeable 
Haemophilus influenzae (28, 29), Acinetobacter baumannii (30), and some strains of 
Pseudomonas aeruginosa (31) and Neisseria meningitides (32).  
 
In conclusion, this study supports the hypothesis that ECV increases PAFR-dependent 
pneumococcal adhesion to upper and lower airway epithelial cells. The impact of regular 
vaping on the risk of pneumococcal airway infection remains to be determined.   
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Legends for Figures 
Figure 1. (a) Platelet-activating factor receptor (PAFR) expression in nasal epithelial cells 
from vaping adults (n=11) prior to experimental E-cigarette vapour exposure (baseline) and 
in non-vaping controls (n=6). There is no difference between the two groups (p =0.18). Data 
are expressed as mean (standard error of the mean) and analysed by t-test, (b) change in 
PAFR expression (expressed as median fluorescence intensity (MFI) adjusted for isotopic 
control) in nasal epithelial cells from adult vapers (n=11), before, and 1 h after, 5 min vaping 
(*p <0.05, paired t test).  
 
Figure 2. (a) Dose-dependent effect of nicotine-free (N-) and nicotine-containing (N+) E- 
cigarette vapour extract (ECV). Increased pneumococcal adhesion, reflected by increased 
colony forming unit count (CFU), is significant at 5% for N- ECV and 2% for N+ ECV, (b) 
effect of 5% N- ECV and N+ ECV on pneumococcal penetration into A549 cells. 
Intracellular bacteria were assessed after treatment with antibiotics to kill cell surface 
bacteria, (c) effect of ECV on platelet-activating factor receptor (PAFR) expression in A549 
cells. Expression was determined by flow cytometry and expressed as median fluorescence 
intensity, (d) effect of the PAFR blocker CV3988 on pneumococcal adhesion to A549 cells 
after exposure to either 5%  N-, or 5% N+ ECV. Data, from either 6 or 7 separate 
experiments, are expressed as median (IQR; interquartile range), and analysed by Kruskal-
Wallis with post-hoc multiple comparison testing. *p <0.05, **p <0.01, ***p  <0.001. 
 
Figure 3. Effect of the antioxidant N-acetyl cysteine (NAC) on pneumococcal adhesion to; 
(a) A549, and (b) BEAS-2B cells cultured with either 5% nicotine-free (N-) E-cigarette 
vapour extract (ECV), or 5% nicotine-containing (N+) ECV. Data, from either 4 or 5 separate 
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experiments, are expressed as median (IQR; interquartile range) and analysed by Kruskal-
Wallis with post-hoc multiple comparison testing. *p <0.05. 
 
Figure 4. Adhesion of S. pneumoniae D39 to; (a) primary nasal HPNEpC cells, (b) primary 
bronchial HBEpC cells, and (c) bronchial cell line BEAS-2B, after exposure to either 5% 
nicotine-free (N-) E-cigarette vapour extract (ECV), 5% nicotine-containing (N+) ECV, or 
DPBS control, with and without incubation with PAFR blocker CV3988. Data from 6 
separate experiments are expressed as median (IQR; interquartile range) and analysed by 
Kruskal-Wallis with post-hoc multiple comparison testing. *p <0.05, and **p <0.01. 
 
Figure 5. Effect of nicotine-free (N-) E-cigarette vapour extract (ECV), and nicotine-
containing (N+) ECV on platelet-activating factor receptor (PAFR) median fluorescence 
intensity (MRI) determined by flow cytometry in; (a) primary nasal HPNEpC cells, (b) 
primary bronchial HBEpC cells, and (c) BEAS-2B cells. Data, from 6 to 10 separate 
experiments, are expressed as median (IQR; interquartile range), and analysed by Kruskal-
Wallis with post-hoc multiple comparison testing. *p <0.05, **p <0.01, and ***p <0.001, (d) 
PAFR MFI in nasal epithelial cells obtained from vapers (n=8) before vaping (baseline), and 
then cultured in vitro with 5% nicotine containing (N+) ECV extract for 2.5 h. Data are 
analysed by paired t test. **p <0.01.  
 
Figure 6. (a) Nasopharyngeal carriage of S. pneumoniae in mice exposed to either nicotine-
free (N-) E-cigarette vapour extract (ECV), or nicotine-containing (N+) ECV, or DPBS 
control. Mice (DPBS controls; n= 17 controls; N- and N+ ECV; n=18) were dosed 
intranasally twice daily with 100% N+ ECV, 100% N- ECV, or DPBS. On the 4th day of 
dosing, mice were infected with 1 x 105 CFU S. pneumoniae. Mice were culled on the 4th day 
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post-infection and nasopharyngeal tissue collected. Colony forming unit count (CFU) values 
of S. pneumoniae are given as count per mL, (b) PAFR expression determined by flow 
cytometry (median fluorescence intensity; MFI) in nasopharyngeal epithelial cells of mice 
after exposure to 100% N+ ECV. Expression was determined on the 4th day of intranasal 
ECV dosing. Data are expressed as mean (SEM) and analysed by one-way ANOVA with 
post hoc comparison testing; *p <0.05, ***p <0.001. 
 
Figure 7. The percentage loss of (a) ascorbate, and (b) glutathione from a synthetic 
respiratory tract lining fluid (RTLF) following a 4 h incubation with 5% nicotine-free (N-) E-
cigarette vapour extract (ECV), and 5% nicotine-containing (N+) ECV. Included in the assay 
is a control particle with low oxidative potential (M120), and a particle with higher oxidative 
potential (SRM-1648). The percentage loss is expressed relative to a particle/ECV-free 
control. Data are expressed as mean (SEM), and analysed by ANOVA with post-hoc multiple 
comparison testing (n=9). **p <0.01, and ***p <0.001. 
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Table 1. Details of vaping participants  
 
†Reported by manufacturer 
 
 
Subject Age Ex-smoker E-cig use E-cigarette E-liquid 
 
Nicotine 
(mg/mL)† 
1 20 Yes (>6m) Daily Kangertech 
subox nano 
Vapor Depot 
Cherry 
1.5 
 
2 20 Yes (> 3m) Daily Gamucci 
Vitesse 
Jelly Bean 8 
3 20 Yes (> 3 m) Daily Kangertech 
subox nano 
Vapour Depot 
Menthol 
0 
4 39 Yes (> 3 m) Daily Blu pro Blu pro 
Tobacco 
18 
5 33 Yes (> 5y) 1-2 
times/week 
Blu pro 
 
Blu pro 
Tobacco 
24 
6 35 Occasional 
(> 8 y) 
Once daily E-cig UK 
 
E-cig UK 
Menthol 
24 
7 35 Yes (> 4 y) Daily E-cig UK 
 
E-cig UK 
Tobacco Royale 
18 
8 23 Yes (> 6 m) Daily Innokin 
 
Ciagra 
Tornado 
Cyclone 
6 
9 49 Yes (> 4 y) Daily iBaccy 
 
iBaccy 
Cherry 
24 
10 23 Yes (> 5 m) Daily Innokin cool 
Fire 
Watermelon 
 
6 
 
11 30 Yes (>4 y) Daily Vype Vype E-liquid 12 
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